In fact, in client-derived xenograft models, downregulating SOAT1 or treatment with the SOAT1 inhibitor avasimibe substantially lowers the size of tumors overexpressing SOAT1 and effectively inhibits HCC proliferation and migration [3]. This evidence concerns the gene SOAT1 and hepatocellular carcinoma.